Welcome to our dedicated page for Orexo Ab news (Ticker: ORXOY), a resource for investors and traders seeking the latest updates and insights on Orexo Ab stock.
Orexo AB (ORXOY) generates a steady stream of news related to pharmaceutical development, drug delivery technology and commercial progress. Company announcements emphasize its proprietary AmorphOX powder-based platform, clinical studies of intranasal rescue medications, and collaborations that extend its technology to new therapeutic areas.
Readers of this news feed can follow updates on Orexo’s work in opioid use disorder treatments in the U.S. market, as well as development projects such as OX124, a high-dose naloxone rescue medication for opioid overdose. Interim reports provide context on revenues, cash flow, and the performance of the U.S. Commercial segment, alongside commentary from management on business development and regulatory interactions.
A significant portion of Orexo’s recent news focuses on the AmorphOX platform and its application to intranasal formulations. This includes clinical and preclinical results for OX640, a nasal epinephrine powder product for severe allergic reactions including anaphylaxis, and preclinical data on powder-based intranasal semaglutide formulations. Company releases describe pharmacokinetic and pharmacodynamic findings, such as absorption profiles, plasma levels and effects on blood pressure and heart rate.
Another recurring news theme is collaboration on nasal powder vaccines. Orexo reports on its partnership with Abera Bioscience to combine AmorphOX with a vaccine platform for mucosal vaccines, including intranasal influenza vaccine candidates. Updates cover proof-of-concept immune response data and the potential implications for vaccine stability and administration.
Investors and observers can also track corporate governance items, such as the composition of the nomination committee for the annual general meeting, and participation in healthcare conferences. Bookmarking this page allows users to monitor Orexo’s clinical milestones, technology developments and financial disclosures as they are released.
Orexo AB (OTCQX: ORXOY) announced a collaboration with ApexB.io and Magellan Rx Management to research its digital therapeutic modia™, aimed at treating opioid use disorder (OUD). The partnership seeks to gather real-world evidence supporting the digital treatment's accessibility. This initiative aligns with CDC calls to combat rising overdose deaths, which surged by 21% to over 83,000 in the U.S. in the past year. Orexo is also advancing other digital therapeutics, deprexis® and vorvida®, in response to growing mental health challenges.
Orexo announces the early redemption of its SEK 500 million senior unsecured callable floating rate bonds originally due in 2021. The bonds will be redeemed in full on March 3, 2021, at a price of 101.50% of the nominal amount plus accrued interest. The record date for this redemption is set for February 24, 2021. To facilitate this process without default, Orexo has received a temporary waiver from the bond agent. Following the redemption, the bonds will be delisted from Nasdaq Stockholm.
Orexo AB has successfully issued senior unsecured callable floating rate bonds worth SEK 500 million, oversubscribed under a SEK 1,000 million framework, maturing in February 2025. These bonds carry a floating interest rate of 3-month Stibor + 375bps per annum and received strong interest from institutional investors. The funds will facilitate the repurchase of existing bonds totaling SEK 77.4 million and early redemption of SEK 148.5 million. This signals investor confidence in Orexo's growth strategy in developing its pipeline and digital therapeutics.
On February 1, 2021, Orexo AB announced its plans to issue senior unsecured callable floating rate bonds worth up to SEK 500 million under a total framework of SEK 1,000 million with a four-year tenor. The proceeds will be used to repay existing bonds and support general corporate purposes. Existing bondholders may subscribe to the new bonds or opt for a premium repurchase of their current holdings. The company aims to enhance its financial flexibility for future investments.
Summary not available.
Orexo has established a Nomination Committee ahead of the 2021 Annual General Meeting (AGM), representing approximately 44% of the company's voting power as of September 30, 2020. The committee includes notable members such as Christian Salling (Novo Holdings A/S), Björn Odlander (HealthCap), and James Noble (Chairman of the Board). Proposals for the AGM include appointments and fees for board members and auditors. Shareholders can submit their proposals by February 12, 2021. The AGM is set for April 13, 2021, amid ongoing monitoring of COVID-19 guidelines.
Orexo AB (OTCQX: ORXOY) invites investors and analysts to a teleconference on October 1, 2020, at 3 pm CET, to discuss updates on its Digital Therapeutics business, focusing on the efficacy of deprexis® and vorvida® therapies. The company will outline commercialization strategies, market access initiatives, and technical platform offerings.
The event will feature CEO Nikolaj Sørensen and key executives, concluding with a Q&A session. Orexo aims to redefine addiction treatment through clinically validated digital solutions.
Orexo AB (OTCQX: ORXOY) has initiated patent infringement litigation against Sun Pharmaceutical Industries in the U.S. District Court for New Jersey. The lawsuit responds to Sun's Abbreviated New Drug Application (ANDA) seeking to market generic versions of Orexo's ZUBSOLV® (buprenorphine and naloxone). Orexo claims that multiple patents protecting ZUBSOLV® are being infringed, with expiration dates from December 2027 to September 2032. This legal action will delay FDA approval of Sun's ANDA for 30 months while the case proceeds. Orexo anticipates increased legal costs primarily in 2021 and 2022.
Orexo has announced a partnership with GoGoMeds to provide digital therapies, deprexis® for depression and vorvida® for alcohol misuse, making them available to those in need. Additionally, OXD01, aimed at treating opioid use disorder, will launch in the U.S. by Q4 2020. The COVID-19 pandemic has increased demand for such digital solutions. The therapies are designed to improve access to mental health care, utilizing AI for tailored content, and are accessible anytime, anywhere. This collaboration seeks to support various addiction services across the U.S.